Lundbeck and Otsuka collaborate on Lu AE 58054 as a treatment for Alzheimers disease

Lundbeck A/S and Otsuka Pharmaceutical company have announced a license and development agreement for Lu AE 58054, for the treatment of Alzheimer's disease. Under the terms of the agreement, Lundbeck will grant Otsuka co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia including Japan, major European countries and Nordic countries.

The pivotal clinical program with Lu AE 58054 is planned to be initiated later in 2013. The global program will consist of several studies and include more than 2,500 patients. The first phase III study will enroll patients with mild-to-moderate Alzheimer's disease. Lu AE 58054 will be tested as adjunct treatment to donepezil. Subsequent studies are expected to be initiated towards the end of 2013.